
Quantum BioPharma Receives BUY Rating and $45 Price Target from Kingswood Capital Partners
Kingswood Capital Partners initiated coverage of Quantum BioPharma with a BUY rating and $45 price target, indicating strong analyst confidence in the company's lead multiple sclerosis treatment candidate Lucid-MS and its potential market success.
Read full story


























